Biosketch

Dr. Gregory Kato is both a senior staff physician with the Critical Care Medicine Department at the NIH Clinical Center and head of the Sickle Cell Vascular Disease Unit at NIH’s National Heart, Lung, and Blood Institute. He is also an adjunct investigator with the Pediatric Oncology Branch of the National Cancer Institute. In addition, he currently is an associate professor of pediatrics at the Johns Hopkins University School of Medicine and the Kimmel Cancer Center at Johns Hopkins.

Dr. Kato received his undergraduate degree from University of California at Los Angeles and his medical degree from the George Washington University School of Medicine and Health Sciences.

He researches the mechanisms of vascular occlusion in sickle cell disease---focusing on the disease of the blood vessel wall that occurs in sickle cell disease, producing pulmonary hypertension and linked to early mortality in these patients.

Honors and Awards

Clinician Scientist Award, Johns Hopkins University School of Medicine, 1998; Young Investigator Award, American Society of Clinical Oncology, 1991; Certificate of Merit, Young Investigator’s Day, Johns Hopkins University School of Medicine, 1990; General Pediatrics Resident Award, Children’s Hospital of Los Angeles, 1987; Frances Nunnally Winzer Resident Award, Children’s Hospital of Los Angeles, 1986; first prize, Bioethics Essay Competition, Academy of Medicine, Washington, DC, 1983

Selected Publications

BOOKS/BOOK CHAPTERS

Kato GJ, Gladwin MT. Sickle cell Disease. From: Principles of Critical Care, Third Edition. Hall JB and Schmidt GA, eds., New York:McGraw-Hill, 2005, pp 1655-1670.

Mack AK, Kato GJ. Sickle cell disease and Nitric Oxide: A paradigm shift? Int J Biochem Cell Biol. 2006; 38:1237-1243.

Aliyu ZY, Tumblin AR, Kato GJ. Current Therapy of Sickle Cell Disease. Haematologica, 2006; 91:7-10.

Kato GJ. Pulmonary hypertension – an emerging problem in sickle cell and other hemolytic anemias. Bloodmed.com, 2006, http://www.bloodmed.com/800000/mini-reviews1.asp?id=240

Kato GJ, Gladwin MT. A Novel Defense against Hemolytic-Oxidative Stress. Blood, 2006; 108:2504-2505

Kato GJ, Gladwin MT, Steinberg MH. Deconstructing Sickle Cell Disease: Reappraisal of the Role of Hemolysis in the Development of Clinical Subphenotypes. Blood Reviews, 2007; 21:37-47

Kato GJ, Gladwin MT. Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia. Hematology Education, 2007; 1:134-139

Kato GJ, Onyekwere OC, Gladwin MT. Pulmonary Hypertension in Sickle Cell Disease: Relevance to Children. Pediatr Hematol Oncol, 2007; 24:159-170

Gladwin MT, Kato GJ. Mechanism of Disease: Hemolysis associated endothelial dysfunction and pulmonary hypertension; an emerging cause of death in the hemoglobinopathies. Adv Pulm Hypertension, 2007; 6:23-30

Kato GJ, Gladwin MT. Hemolysis-associated pulmonary hypertension in sickle cell disease and thalassemia. Hematology Education: the education program for the annual congress of the European Hematology Association, in press

JOURNAL ARTICLES

Morris CR, Kato G, Poljakovic M, Blackwelder WC, Hazen S, Vichinsky EP, Morris SM Jr, Gladwin M. Dysregulated arginine metabolism contributes to endothelial dysfunction, pulmonary hypertension and mortality in sickle cell disease. JAMA 2005;294: 81-90

Kato GJ, Martyr S, Blackwelder WC, et al. Levels of soluble endothelium-derived adhesion molecules in patients with sickle cell disease are associated with pulmonary hypertension, organ dysfunction, and mortality. Br J Haematol 2005;130:943-53

Kato GJ, McGowan V, Machado RF, Little JA, Taylor VI JA, Morris CR, Nichols JS, Wang X, Poljakovic M, Morris Jr. SM, Gladwin MT. Lactate dehydrogenase as a biomarker of hemolysis-associated nitric oxide resistance, priapism, leg ulceration, pulmonary hypertension and death in patients with sickle cell disease. Blood 2006; 107:2279-85

Kato GJ, Hsieh M, Machado R, Taylor J 6th, Little J, Butman JA, Lehky T, Tisdale J, Gladwin MT. Cerebro-vascular disease associated with sickle cell pulmonary hypertension. Am J Hematol 2006; 81:503-10

Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT; MSH Investigators. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006;296:310-8

Kato GJ, Gladwin MT, Steinberg MH. Deconstructing Sickle Cell Disease: Reappraisal of the Role of Hemolysis in the Development of Clinical Subphenotypes. Blood Reviews, 2007; 21:37-47

Sachdev V, Machado RF, Shizukuda Y, Rao Y, Sidenko S, Ernst I, St. Peter M, Coles WA, Rosing D, Blackwelder WC, Castro O, Kato GJ, Gladwin MT. Diastolic Dysfunction is an Independent Risk Factor for Death in Patients with Sickle Cell Disease. J Am Coll Cardiol. 2007; 49:472-9

Machado RF, Mack AK, Martyr S, Barnett C, MacArthur P, Sachdev V, Ernst I, Hunter LA, Coles WA, Nichols JP, Kato GJ, and Gladwin MT. Severity of Pulmonary Hypertension During Vaso-occlusive Pain Crisis and Exercise in Patients with Sickle Cell Disease. Br J Haematol. 2007; 136:319-25

Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, Kato G, Munson PJ, Morris SM Jr, Gladwin MT. Amplified expression profiling of platelet transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. Circulation. 2007;115:1551-62